Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) price on Wednesday, January 15, rose 3.12% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $36.73.
A look at the stock’s price movement, the close in the last trading session was $35.62, moving within a range at $35.76 and $37.4175. The beta value (5-Year monthly) was 0.619. Turning to its 52-week performance, $62.53 and $35.24 were the 52-week high and 52-week low respectively. Overall, CRNX moved -33.96% over the past month.
Crinetics Pharmaceuticals Inc’s market cap currently stands at around $3.41 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Wall Street analysts have also projected the company’s year-on-year revenue to grow to 1.57M, representing a -60.84% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CRNX is a 100% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend CRNX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CRNX’s current price about -25.72% and -32.20% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 22.02, while 7-day volatility ratio is 9.06% and 5.36% in the 30-day chart. Further, Crinetics Pharmaceuticals Inc (CRNX) has a beta value of 0.62, and an average true range (ATR) of 2.67. Analysts have given the company’s stock an average 52-week price target of $69, forecast between a low of $69 and high of $69. Looking at the price targets, the low is -87.86% off current price level while to achieve the yearly target high, price needs to move -87.86%. Nonetheless, investors will most likely welcome a -87.86% jump to $69 which is the analysts’ median price.
If we refocus on Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), historical trading data shows that trading volumes averaged 1.09 over the past 10 days and 754.58K over the past 3 months. The company’s latest data on shares outstanding shows there are 92.74 million shares.
The 6.31% of Crinetics Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 88.25% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.92 million on 2024-12-31, giving us a short ratio of 9.82. The data shows that as of 2024-12-31 short interest in Crinetics Pharmaceuticals Inc (CRNX) stood at 760.0 of shares outstanding, with shares short rising to 6.01 million registered in 2024-11-29. Current price change has pushed the stock -28.16% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CRNX stock continues to rise going into the next quarter.
